Company intelligence / Profile preview

IntegoGen

Tallahassee, Florida, United Statesaatb.org ↗

Ownership: Private
Development stage: Commercial

Overview

IntegoGen has developed placental/amniotic membrane-derived biologic implants for use in surgical and regenerative medicine applications. Their lead program AMP‑001 was evaluated in a Phase 1 clinical trial for hidradenitis suppurativa but the study was withdrawn. Another product, surgiGRAFTnano, is pending further development. The company is AATB-accredited and FDA registered as an HCT/P 361 manufacturer/distributor of birth-tissue derived products[1][2][4].

Therapeutic areas: OtherNeurologyDermatologyRheumatology
Modalities: BiologicTissue-derived productAllogeneic tissue implantDecellularized tissue matrix (placental/amniotic membrane)
Industry: Biotech

Drug pipeline

1 asset

AMP-001

Unknown

Partnerships

Alliant Biotech LLC (distribution partner for STA Implants)[2]

Beyond the preview

Go deeper on IntegoGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntegoGen.

Explore the full profile